Trisubstituted Phenolic compounds as inhibitors of Acetylcholinesterase and Amyloid beta aggregate formation

Current Enzyme Inhibition

Volumn 9, Issue 1, 2013, Pages 67-74

  Peckels, Caroline M ^a   Alexander, Nathan S ^b   Wilson, Gina N ^b   Karty, Joel M ^a   Matera, Kathryn M ^a  

^a ELON UNIVERSITY   (United States)

^b BALDWIN WALLACE COLLEGE   (United States)

Author keywords

Acetylcholinesterase; Aggregation; Alzheimer's disease; Amyloid beta; Dual inhibitors; Phenol

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; ELLAGIC ACID; GALLIC ACID; JUGLANS REGIA EXTRACT; PHENOL DERIVATIVE; PLANT EXTRACT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; ENZYME ASSAY; ENZYME MECHANISM; PROTEIN AGGREGATION;

EID: 84877324380     PISSN: 15734080     EISSN: 18756662     Source Type: Journal    
DOI: 10.2174/1573408011309010009     Document Type: Article

References (32)

1. Galimberti, D.; Scarpini, E. Disease-modifying treatments for Alzheimer's disease. Ther. Adv. Neurol. Disord., 2011, 4, 203-216.
2. Xiaoning, B. Alzeheimer disease: update on basic mechanisms. J. Am. Osteopath. Assoc, 2010, 110, S3-S9.
3. Alvarez, A.; Alarcon, R.; Opazo, C; Campos, E.O.; Munoz, F.J.; Calderon, F.H.; Dajas, F.; Gentry, M.K.; Doctor, B.P.; De Mello, F.G.; Inestrosa, N.C. Stable complexes involving acetylcholinesterase and amyloid-p peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. J. Neurosci., 1998, 18, 3213-3223.
4. Tornic, J.L.; Pensalfini, A.; Head, E.; Glabe, D.G. Soluble fibrillar oligomer levels are elevated in Alzheimer disease brain and correlate with cognitive dysfunction. Neurobiol. Dis., 2009, 35, 352-358.
5. Selkoe, D.J. Presenilin, notch and the genesis and treatment of Alzheimer's disease. PNAS, 2001, 98, 11039-11041.
6. Haass, C; Selkoe, D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid p-peptide. Nat. Rev. Mol. Cell Biol, 2007, 8, 101-112.
7. Alvarez, A.; Opazo, C; Alarcon, R.; Garrido, J.; Inestrosa, N.C. Acetylcholinesterase promotes the aggregation of amyloid-p-peptide fragments by forming a complex with the growing fibrils. J. Mol. Biol, 1997, 272, 348-361.
8. Inestrosa, N.C; Alvarez, A; Perez, C.A; Moreno, R.D.; Vicente, M.; Linker, C; Casanueva, O.I.; Soto, C; Garrido, J. Acetylcholinesterase accelerates assembly of amyloid-p-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron, 1996, 16, 881-891.
9. Johnson, G.; Moore, S.W. The Adhesion function on acetylcholinesterase is located at the peripheral anionic site. Biochem. Biophys. Res. Commun., 1999, 258, 758-762.
10. Munoz-Ruiz, P.; Rubio, L.; Garcia-Palomero, E.; Dorronsoro, I.; del Monte-Millan, M.; Valenzuela, R.; Usan, P.; de Austria, C; Bartolini, M.; Andrisano, V.; Bidon-Chanal, A.; Orozco, M.; Luque, F.J.; Medina, M.; Martinez, A. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease J. Med. Chem., 2005, 48, 7223-7233.
11. Luo, W.; Li, Y-P.; He, Y.; Huang, S-L.; Tan, J-H.; Ou, T-M.; Li, D.; Gu, L-Q.; Huang, Z-S. Design, synthesis and evaluation of novel tacrine-multialkoxybenzene hybrids as dual inhibitors for cholinesterases and amyloid beta aggregation. Bioorg. Med. Chem., 2011, 19, 763-770.
12. Huang, L.; Shi, A.; He, F.; Li, X. Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg. Med. Chem., 2010, 18, 1244-1251.
13. Ellman, G.L.; Courtney, K.D.; Andres, V.; Featherstone, R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol, 1961, 7, 88-95.
14. Chauhan, N.; Wang, K.C.; Wegiel, J.; Malik, M.N. Walnut extract inhibits the fibrillization of amyloid beta-protein, and also defibrillizes its preformed fibrils. Curr. Alzheimer Res., 2004, 1, 183-188.
15. Klunk, W.E.; Jacob, R.F.; Mason, R.P. Quantifying amyloid p-peptide aggregation using the congo red-Ap spectrophotometric assay. Anal. Biochem., 1999, 266, 66-76.
16. Klunk, W.E.; Pettegrew, J.W.; Abraham, D.J. Quantitative evaluation of CR binding to amyloid-like proteins with a beta pleated sheet conformation. J. Histochem. Cytochem., 1989, 37, 1273-1281.
17. Darvesh, A.S.; Carroll, R.T.; Bishayee, A.; Geldenhuys, W.J.; Van Der Schyf, C.J. Oxidative stress and Alzheimer's disease: dietary polyphenols as potential therapeutic agents. Expert Rev. Neurother., 2010, 10, 729-745.
18. Rossi, L.; Mazzitelli, S.; Arciello, M.; Capo, C.R.; Rotilio, G. Benefits from dietary polyphenols for brain aging and Alzheimer's disease. Neurochem. Res., 2008, 33, 2390-400.
19. Singh, M.; Arseneault, M.; Sanderson, T.; Murthy, V.; Ramassamy, C. Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms. J. Agric. Food Chem., 2008, 56, 4855-4873.
20. Feng, Y.; Yang, S.G.; Du, X.T.; Zhang, X.; Sun, X.X.; Zhao, M.; Sun, G.Y.; Liu, R.T. Ellagic acid promotes Abeta42 fibrillization and inhibits Abeta42-induced neurotoxicity. Biochem. Biophys. Res. Commun., 2009, 390, 1250-1254.
21. Stains, C.I.; Mondal, K.; Ghosh, I. Molecules that target beta-amyloid. Chem. Med. Chem., 2007, 2, 1674-1692.
22. Sussman, J.L.; Harel, M.; Frolow, F.; Oefner, C.; Godman, A.; Toker, L.; Silman, I. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science, 1991, 253, 872-879.
23. Harrel, M.; Schalk, I.; Ehret-Sabatier, L.; Bouet, F.; Goeldner, M.; Hirth, C.; Axelsen, P.H.; Silman, I.; Sussman, J.L. Quarternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. PNAS, 1993, 90, 9031-9035.
24. Sussman, J.L.; Silman, I. Acetylcholinesterase: structure and use as a model for specific cation-protein interactions. Curr. Opin. Struct. Biol., 1992, 2, 721-729.
25. Ordentlich, A.; Barak, D.; Kronman, C.; Ariel, N.; Segall, Y.; Velan, B.; Shafferman, A. Functional characteristics of the oxyanion hole in human acetylcholinesterase. J. Biol. Chem., 1998, 273, 19509-19517.
26. Johnson, G.; Moore, S.W. The peripheral anionic site of acetylcholinesterase: structure, functions and potential role in rational drug design. Curr. Pharm. Des., 2006, 12, 217-225.
27. Barak, D.; Kronman, C; Ordentlich, A.; Ariel, N.; Bromberg, A.; Marcus, D.; Lazar, A.; Velan, B.; Shafferman, A. Acetylcholinesterase peripheral anionic site degeneracy conferred by amino acid arrays sharing a common core. J. Biol. Chem., 1994, 269, 6296-6305.
28. Porat, Y.; Abramowitz, A.; Gazit, E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem. Biol. Drug Des., 2006, 67, 27-37.
29. Maezawa, I.; Hong, H-S.; Liu, R.; Wu, C-Y.; R. Cheng, R.H. Kung, M-P. Kung, H.F. Lam, K.S. Oddo, S. LaFerla, F.M. Jin, L.W. Binding affinity of CR to amyloid beta oligomers. J. Neurochem., 2008, 104, 457-468.
30. Armstrong, A.H.; Chen, J.; McKoy, A.F.; Hecht, M.H. Mutations That Replace Aromatic Side Chains Promote Aggregation of the Alzheimer's Aβ Peptide. Biochemistry, 2011, 50, 4058-4067.
31. Necula, M.; Kayed, R.; Milton, S.; Glabe, C.G. Small molecule inhibitors of aggregation indicate that amyloid β oligomerization and fibrillization pathways are independent and distinct. J. Biol. Chem., 2007, 282, 10311-10324.
32. Szegletes, T.; Mallender, W.D.; Rosenberry, T.L. Non-equilibrium analysis alters the mechanistic interpretation of inhibition of acetylcholinesterase by peripheral site ligands. Biochemistry, 1998, 37, 4206-4216.